Catalyst Event
Samchundang Pharm Co Ltd (000250) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
5/11/2026, 12:00:00 AM
South Korea's Financial Supervisory Service (FSS) officially stated it is closely monitoring Samchundang Pharm following recent controversies over public disclosures and stock price volatility on 2026-05-11. The FSS also announced plans to issue new disclosure guidelines for bio-pharma companies by the end of June 2026, with an expected price impact of ≥10%.
Korean Translation
금융감독원, 공시 논란 및 주가 변동성과 관련하여 2026-05-11 삼천당제약을 예의주시하고 있다고 공식 발표함. 또한 이 사례를 계기로 2026년 6월 말까지 제약·바이오 기업 공시 가이드라인을 발표할 계획이며, 10% 이상의 주가 변동이 예상됨.
Related Recent Events
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Lirafugratinib as a second-line treatment for bile duct cancer, which was granted priority review and carries an estimated >10% price impact, scheduled.
9/27/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
FDA decision on New Drug Application for Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer, following a 'Class 2' resubmission in January 2026 and carrying an estimated >10% price impact, scheduled.
7/23/2026, 12:00:00 AM
Sino Biopharmaceutical Ltd (1177) · Other
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
6/24/2026, 12:00:00 AM
Innovent Biologics Inc (1801) · Other
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
6/5/2026, 12:00:00 AM
SK Biopharmaceuticals Co Ltd (326030) · Other
SK Biopharmaceuticals is scheduled to be removed from the MSCI Korea Index effective at the close of May 29, 2026, following an announcement on May 12, 2026, which may lead to passive fund outflows, scheduled. Medium impact estimated due to expected passive fund outflows.
5/29/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
5/27/2026, 12:00:00 AM